HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bodybuilding.com Hoists Its Regulatory Experience As Lesson For Compliance

This article was originally published in The Rose Sheet

Executive Summary

Highlighting dietary supplement sector's self-regulation at a recent supplement industry regulatory conference, the sports nutrition product marketer's chief counsel Bill Carter described his experience in federal court in 2012. He suggested some supplement firms, like Bodybuilding.com previously, don't consider themselves likely to incur litigation or criminal charges linked to regulatory problems when they learn about other businesses that have. "Just because you don't hear about a lot of FDA's office of Criminal Investigations doesn't mean they're not active," he said.

You may also be interested in...



US Supplement Market Growth: Is The Industry In Its Own Way?

Longtime supplement industry attorney Scott Bass says supplement manufacturers should work with FDA as an ally, including registering products with the agency pre-market, while FDA's second-in-command for supplement industry oversight, Robert Durkin, says the agency is not interested in preventing more safe products from reaching the market.

Steroids Sold As Supplements Targeted In FDA Actions, Congressional Hearing

Enhanced FDA enforcement against steroid products sold as dietary supplements is likely reassuring to law-abiding supplement companies

Symptoms Change But Savings OTC Drugs Deliver For US Health Care Spending Continue Growing

Substantially more consumers in 2022 report sleep issues, allergies and skin problems than in 2018 while using quit smoking aids has dropped, according to CHPA’s latest “Value of OTC Medicines” survey. Average annual household spending on OTCs is $645.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS121692

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel